Sheet 1 of 2

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

NOV 1 9 2001 3

ATTY. DOCKET NO. 4-31193A APPLICATION NO. 09/817,487 APPLICANT PIPPIG ET AL. FILING DATE MARCH 26, 2001

Group 1646

U	I.S.	PA	TEN	TL	DO	CU	IM	FN.	TS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA			47.			
	AB						
	AC						
	AD						
	AE						-
	AF						
	AG						
	АН						
	AI						
•	AJ						
	AK	*					
	AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
 AM							
 AN							
 AO							
AP							
 AQ							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

FY	/ AMINI	FP	Q A DATE CONSIDERED	
		АТ	Hildinger, et al., "Bicistronic Retroviral Vectors for Combining Myeloprotection with Cell-Surface Marking," Gene Therapy, 6:1222-1230 (1999)	•
		AS	International Search Report for PGT/EP01/03543, dated September 10, 2001 Considered; Do Not Print.	,
RLi		AR	Glass, et al., "Kinase Domain of the Muscle-Specific Receptor Tyrosine Kinase (MuSK) is Sufficie for Phosphorylation but not Clustering of Acetylcholine Receptors: Required Role for the MuSK Ectodomain?" <i>Proc. Natl. Acad. Sci. USA</i> , 94:8848-8853 (August 1997)	nt (A)

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if nec ssary)

ATTY. DOCKET NO. 4-31193A APPLICATION NO. 09/817,487 APPLICANT 說PPIG ET AL. **EILING DATE** MARCH 26, 2001

Group 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

RL:	AA	Zhou, et al., "Distinct Domains of MuSK Mediate Its Abilities to Induce and to Associate with Postsynaptic Specializations," <i>The Journal of Cell Biology</i> , 146(5):1133-1146 (September 6, 1999)
	АВ	
	AC	
	AD	
	AE	
	AF.	
	AG	
	ΑḤ	
	AI	
	AJ	
	AK	
	AL	
	АМ	
	AN	
EXAMINER		Ruidians P DATE CONSIDERED

8/24/2002

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several Deets if neosesary)

ATTY. DOCKET NO. 4-31193A APPLICATION NO. 09/817,487 **APPLICANT** PIPPIG ET AL. **FILING DATE** MARCH 26, 2001

Group 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
RLi	AA	5,521,295	5/28/96	Pacifici, et al.			11/8/94
RLi	AB	5,656,473	8/12/97	Valenzuela, et al.	-		1/19/95
	AC						
	AD						
	AE				e		
	AF						
	AG					-	
	АН						
	Al						
	AJ					···a	
	AK					, . %	. *
	AL					:	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
Rhi	AM	WO 95/06723 • -	3/9/95	PCT		- X		10
RLi	AN	WO 98/19540 🎜 /	5/14/98	PCT				-
	AO		0					
	AP	·						
	AQ							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	Ĺ	Genbank AF006464
	AR	
		Genbank NM005592
	AS	
		0 1 1104005
	 -	Genbank U34985
	AT	
FYAMINI	ED.	DATE CONCIDERED

DATE CONSIDERED

8/24horz

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

P(Le several sheets if necessary)

ATTY. DOCKET NO. 4-31193A APPLICATION NO. 09/817,487 **APPLICANT** PIPPIG ET AL. FILING DATE

Group

Sheet 2 f 2

1646

MARCH 26, 2001

TE TRADEN	ARK	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
RLi	AA	Glass, et al., "Agrin acts via a MuSK receptor complex," Cell, 85:513-523 (May 17, 1996)
	АВ	Hesser, et al., "Identification and characterization of a novel splice variant of MuSK," <u>FEB Letters</u> , 442:133-137 (1999)
	AC	Jolly, et al., "Isolation and characterization of a full-length expressible cDNA for human hypoxanthine phosphoribosyltransferase," Proc. Natl. Acad. Sci. USA , 80:477-481 (January 1983)
	AD	Kashles, et al., "A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization," Molecular and Cell Biology, 11(3):1454-1463 (March 1991)
	AE	Norris, et al., "High-titer MSCV-based retrovirus generated in the pCL acute virus packaging system confers sustained gene expression in vivo," <u>J. Virol. Methods</u> , 75:161-167 (1998)
	AF	Pawliuk, et al., "Sustained high-level reconstitution of the hematopoietic system by preselected hematopoietic cells expressing a transduced cell-surface antigen," <u>Human Gene Therapy</u> , 8:1595-1604 (September 1, 1997)
	AG	Persons, et al., "Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo," <u>Blood</u> , 90(5):1777-1786 (September 1, 1997)
	АН	Reddy, et al., "Transient expression of full-length and truncated forms of the human nerve growth factor receptor," Molecular Brain Research, 8:137-141 (1990)
	AI	Valenzuela, et al., "Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury," Neuron, 15:573-584 (September 1995)
V	AJ	van der Geer, et al., "Receptor protein-tyrosine kinases and their signal transduction pathways," Annual Review of Cell Biology, 10:251-337 (1994)
	AK	
·	AL	
	АМ	
	AN	
EXAMINER	2.	O A DATE CONCIDENT

Rushing L.

8/24/2002

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Includ a copy of this form with the next communication to applicant.